Synthetic Biology Market Analysis 2026

Additional Insights From Synthetic Biology Market

Investments and Funding in the Global Synthetic Biology Market

Colossal Biosciences – $200 Million Series C

In January 2025, Colossal Biosciences, known for its ambitious efforts to bring back extinct species like the thylacine, dodo, and woolly mammoth, announced it secured an additional $200 million in a Series C funding round led by TWG Global. This latest investment brings the company’s total funding to $435 million and values it at $10.2 billion.

This funding strengthens Colossal Biosciences’ financial position, enabling accelerated research and development toward groundbreaking de-extinction and conservation projects.

(Source:https://colossal.com/colossal-biosciences-raises-200-million-for-de-extinction-efforts/)

Latent Labs – $50?Million Startup Funding

Latent Labs, a company developing AI foundation models to make biology programmable, has come out of stealth mode with $50 million in total funding to accelerate its progress and partnerships. Founded by Dr. Simon Kohl, former co-lead of DeepMind’s protein design team and senior scientist on the Nobel Prize-winning AlphaFold2 project, the funding round includes a $40 million Series A led by Radical Ventures and Sofinnova Partners, alongside investors like Flying Fish, Isomer, 8VC, Kindred Capital, and Pillar VC. Notable angel investors supporting the company include Google Chief Scientist Jeff Dean, Aidan Gomez—the inventor of Transformer architecture and founder of Cohere—and Mati Staniszewski, founder of ElevenLabs. This funding empowers Latent Labs to accelerate the development of AI-driven biological programming technologies and expand strategic collaborations in synthetic biology

(Source:https://www.latentlabs.com/press-release/latent-labs-secures-50m-in-funding/)

Trade Analysis/Import Export Analysis in the Global Synthetic Biology Market

Export landscape

North America, particularly the United States, leads the global export market for synthetic biology products and tools, driven by its advanced biotech infrastructure and significant R&D investments. European countries like Germany and the UK are also key exporters, focusing on pharmaceuticals, industrial enzymes, and renewable bio-based products. Emerging markets such as China and India are rapidly expanding their export capabilities, fueled by government initiatives and growing biotech sectors. The increasing demand for sustainable and synthetic bio-products worldwide is pushing exports higher, with specialized biologics and engineered enzymes dominating trade flows.

(Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC4685481/)

Import dynamics

Countries with developing synthetic biology sectors, including India and several in Latin America, rely heavily on imports of advanced tools, genetic materials, and reagents primarily from North America and Europe. Imports include critical components like DNA synthesis kits, cell cultures, and specialized enzymes required for research and commercial applications. The import volumes are increasing steadily as these regions scale up biotech R&D and industrial production, though trade imbalances often exist due to nascent local manufacturing capabilities. Regulatory barriers and quality standards in importing countries also influence the flow and cost of these imports.

(Source:https://www.tradeimex.in/blogs/europe-trade-trends-2025-imports-exports-analysis)

Trade implications

The expanding global trade in synthetic biology products raises several implications including the need for harmonized regulatory standards to facilitate cross-border exchange while ensuring biosafety and ethical compliance. Trade tensions and intellectual property considerations can impact collaboration and distribution networks. Additionally, as synthetic biology becomes central to sustainability goals, trade policies increasingly focus on bio-based product certifications and environmental impact assessments. Market players must navigate complex export controls, import tariffs, and biosafety regulations, which may influence supply chain resilience and competitive positioning.

(Source:https://www.infosys.com/services/data-analytics/documents/intelligent-supply-chains.pdf)

Pricing Trend in the Global Synthetic Biology Market

Declining cost of DNA synthesis

Advances in enzymatic DNA synthesis have led to a 20–50% reduction in costs, falling from $0.10 per base pair in 2023 to between $0.05 and $0.08 in 2025. Meanwhile, CRISPR gene editing expenses have dropped by 20–30%, reaching $20,000–$25,000 per genome edit, thanks to breakthroughs in enzymatic synthesis and semiconductor-scale manufacturing. These cost declines are making gene synthesis quicker and more affordable, expanding accessibility for researchers and startups, and driving faster innovation in drug discovery, bioengineering, and industrial biotech.

(Source:https://quickmarketpitch.com/blogs/news/synthetic-biology-how-big)

Reduction in CRISPR gene editing costs

Similarly, the cost of CRISPR gene editing has declined, although eight publicly traded CRISPR companies have seen their stock prices drop by about 50% over the past year, with most down over 75% from their 2021 highs. Advances in CRISPR efficiency, delivery methods, and automation have contributed to cost reductions, allowing smaller biotech firms and academic institutions greater access to gene editing technologies. This shift is broadening the market and accelerating progress in therapeutic research and development. These cost reductions and improved accessibility are helping to diversify the market, encouraging innovation and enabling a wider range of players to contribute to advancements in synthetic biology despite short-term financial volatility.

(Source:https://www.statnews.com/2025/02/06/crispr-gene-editing-medical-breakthrough-not-matched-by-financial-success/)

Patent Analysis in the Global Synthetic Biology Market

(Source:https://patents.google.com/patent/US8697359B1/en)

Key Conferences and Events in the Global Synthetic Biology Market

Regulatory Scenario in the Global Synthetic Biology Market

North America

In the United States, synthetic biology operates within existing biotechnology laws per the Coordinated Framework for Regulation of Biotechnology. Oversight is divided among three key federal agencies: APHIS (USDA) handles plant-related organisms, FDA regulates therapeutics, and EPA oversees environmental impacts. The policy emphasizes product-based safety assessment rather than method-based regulation. However, critics argue that this patchwork lacks clarity on responsibilities and may not fully address novel SynBio risks like therapeutic organisms that can evolve in vivo.?
(Source:https://www.aphis.usda.gov/biotechnology/regulations 
(Source:https://www.fda.gov/food/agricultural-biotechnology/how-gmos-are-regulated-united-states)

Europe

The EU employs a robust, precautionary framework under GMO Directives (2001/18/EC and 2009/41/EC), requiring case-by-case risk assessments, mandatory labeling, traceability, and public consultations. Synthetic biology products are typically regulated as GMOs—even genome-edited or precision-bred organisms. Member states may further restrict or ban cultivation of approved GMOs.?
In the UK, regulations like the Health and Safety at Work Act, the Contained Use Regulation, and the Genetic Technology (Precision Breeding) Act 2023 govern contained SynBio use, release, and licensing with a focus on risk assessments and biosafety. Anti-bioterrorism laws and patent rules also apply. 
(Source:https://food.ec.europa.eu/document/download/136ac61d-b67a-40de-9654-200b606baa48_en?filename=gmo_mod-bio_stake-cons_stake-reply-102.pdf)

Asia-Pacific

In China, the Office of Agricultural Genetic Engineering Biosafety Administration oversees GMO and SynBio applications, applying existing biosafety laws rather than dedicated SynBio rules.?
India regulates synthetic biology through institutional biosafety frameworks such as IBSC, RCGM, and GEAC. However, explicit SynBio policies are still under development, with a growing need for coordinated oversight.?
 Other Asia-Pacific countries—including Australia (via the Office of the Gene Technology Regulator and Therapeutic Goods Administration) and Singapore (under the Biological Agents and Toxins Act)—regulate SynBio as GMOs. Regulatory reliance and digitalization efforts are advancing across the region.?
(Source:https://ogtr.gov.au/about-ogtr/australias-gene-technology-regulatory-system)

South America

Regulation varies: countries like Brazil, Argentina, and Chile have GMO policies that are sometimes extended to synthetic biology. However, most national frameworks remain underdeveloped, with limited funding, weak industry ecosystems, and few dedicated SynBio regulations. Open science initiatives and student programs like iGEM help compensate for policy gaps.?
(Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC11459211/)

Middle East & Africa

In Africa, the COMESA regional body provides shared oversight for GMOs, but final regulatory decisions lie with individual countries. Some nations (e.g., Nigeria, Zimbabwe) have updated biosafety laws to explicitly include SynBio, though enforcement frameworks remain inconsistent.  In the Middle East, specific synthetic biology regulation is limited. For example, Saudi Arabia’s NEOM initiative encourages genetic engineering in agriculture, but broader national SynBio rules are still nascent.?
(Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC4519696/)

Overall, regions differ significantly in their approach to synthetic biology: while North America and Europe have established frameworks—albeit with criticisms—the Asia-Pacific and South America are building capacity within existing GMO structures, often adapting or expanding them. Africa and the Middle East are in early regulatory stages, with sporadic updates and limited enforcement. The global governance landscape remains dynamic, with growing calls for international biosecurity coordination as technologies evolve.

Unmet Needs in the Global Synthetic Biology Market

Skills & expertise gap in bioinformatics and engineered biology

Despite rapid technological progress, there remains a profound shortage of professionals skilled in both wet-lab biology and computational modeling—especially in areas like metabolic modeling, AI-driven bio-design, and digital twin creation. This talent gap limits the ability of companies to scale, standardize processes, and implement advanced synthetic biology systems at industrial levels

(Source:https://royalsocietypublishing.org/doi/10.1098/rsta.2023.0384#:~:text=The%20body%20of%20relevant%20knowledge,for%20validation%20of%20model%20predictions)

Insufficient scale-up capacity & industrial manufacturing infrastructure

Many synthetic biology innovations remain trapped at lab or pilot scale due to limited industrial-grade biomanufacturing facilities. The current industry lacks adequate infrastructure for high-volume fermentation, downstream processing, and continuous production. Even recent investments in new factories are far from meeting demand, posing a bottleneck for broader adoption in food, materials, and biofuels

(Source:https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/02/synthetic-biology-in-focus_42893a6a/3e6510cf-en.pdf)

These gaps underscore a broader unmet need: bridging advanced research with scalable production and operational expertise to move synthetic biology from proof-of-concept to commercial reality.

Competetive Landscape of Synthetic Biology Market

Which are the Major Players in Synthetic Biology Marekt?

• Thermo Fisher Scientific Inc. 
• Merck KGaA 
• Novozymes A/S 
• Eurofins Scientific 
• Agilent Technologies Inc. 
• Ginkgo Bioworks
• Others 

Major established players in the synthetic biology market include Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, Eurofins Scientific, Agilent Technologies Inc., and Ginkgo Bioworks. These companies dominate through their extensive product portfolios, cutting-edge technologies, and global presence across life sciences, pharmaceuticals, industrial biotech, and diagnostics. For example, Thermo Fisher Scientific is recognized as a leader due to its broad range of synthetic biology tools and integrated solutions that support gene editing, DNA synthesis, and bioinformatics, enabling faster research and development processes. Their continued innovation and strategic acquisitions have solidified their position at the forefront of the synthetic biology ecosystem.

In July 2023, Sumitomo Chemical Co., Ltd and Ginkgo Bioworks announced the launch of a new initiative to create functional chemicals through synthetic biology, further strengthening their ongoing biomanufacturing collaboration.

Which are the Emerging Players from Synthetic Biology Market?

• Senti Biosciences
• Mammoth Biosciences
• Synlogic
• Zymergen
• Evolva
• Others

Several emerging players are rapidly gaining traction in the synthetic biology market, including Senti Biosciences, Mammoth Biosciences, Synlogic, Zymergen, and Evolva. These companies focus on innovative applications ranging from gene circuit design and synthetic therapeutics to sustainable chemical production and bio-based materials. For instance, Senti Biosciences is making waves with its pioneering work in synthetic gene circuits for cell therapies, aiming to develop safer and more effective treatments. Its recent funding rounds and partnerships with major pharmaceutical firms highlight its potential as a rising leader in the field.

(Source:https://www.senti.bio/news)

The synthetic biology market is currently fragmented, characterized by a large number of players ranging from established multinational corporations to numerous innovative startups and niche companies. This fragmentation stems from the broad applicability of synthetic biology across diverse sectors such as healthcare, agriculture, industrial biotech, and environmental solutions, which encourages specialization and the emergence of various technology platforms. Additionally, the rapid pace of technological advancements and ongoing research fosters continuous entry of new players, preventing market consolidation. However, as the industry matures, strategic partnerships, mergers, and acquisitions are increasingly common, signaling a gradual move toward consolidation in select segments.

Recent Developments in the Global Synthetic Biology Market

CB

Chidanand Bilagi Verified Analyst

Senior Research Associate at Cognitive Market Research · Cognitive Market Research

Chidanand Bilagi is a Senior Research Associate at Cognitive Market Research and Consulting, specializing in the chemical and materials industry. With a strong focus on global chemical markets, advanced materials, specialty chemicals, sustainable materials, and emerging industrial innovations, he delivers in-depth market intelligence and strategic insights to support informed decision-making.

His expertise includes analyzing industry trends, competitive landscapes, supply chain dynamics, regulatory developments, raw material pricing patterns, and technological advancements shaping the future of the chemical and materials sector. Through rigorous research and data-driven analysis, Chidanand contributes to the development of comprehensive market reports, helping businesses, investors, and industry stakeholders identify opportunities and address challenges in an evolving global market landscape.

Read more

LinkedIn Profile Book a free Consultation